Navigation Links
Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference
Date:9/9/2009

NORTH BILLERICA, Mass., Sept. 9 /PRNewswire/ -- Seahorse Bioscience, Inc., the leader in the design and development of instruments for assessing cellular bioenergetics, today announced it will present data with the University of Nebraska demonstrating the power of the XF Extracellular Flux Analyzer in revealing the effects of KSR1 and nutrients on oxidative phosphorylation and aerobic glycolysis in cancer cells. The data will appear in two posters at the AACR Metabolism and Cancer Conference to be held September 13-16th in La Jolla, CA.

The first poster, "The molecular scaffold, Kinase Suppressor of Ras 1 (KSR1), potentiates H-RasV12 induced transformation and expands cellular capacity for glycolysis and oxidative phosphorylation," reveals unexpected changes in glucose uptake and redirection from bioenergetic pathways to biosynthetic pathways with KSR1 expression in MEF, suggesting that KSR1 optimizes substrate metabolism in Ras-transformed cells. "Our collaboration with Seahorse allowed us to take gene array data and connect it directly to cellular metabolic activity, "observed Dr. Rob Lewis, Professor in the Eppley Cancer Institute at the University of Nebraska Medical Center and poster co-author. "We are now actively exploring new connections among genes, metabolism, and oncogenesis."

The second poster, "Monitoring the flux of glucose, glutamine and metabolic intermediates in tumor cells: excessive nutrients are necessary for cellular metabolic transformation," shows the effects of excessive nutrients in tumor cells beyond the Warburg effect, including shifts in substrate flux in both the bioenergetic and the biosynthetic pathways.

"We undertook this collaboration to show how the XF may be used to uncover novel metabolic aspects of various cancers," stated Dr. Min Wu, Director of Applications Development with Seahorse Bioscience and co-author on both posters. "The work of Dr. Lewis's shows the importance of genes in mitogen signaling pathways in malignant transformation, while my lab is beginning to show the importance of nutrients in determining the outcomes of cancer phenotypes. This would have been very difficult to detect without the XF Analyzer."

About Seahorse Bioscience

Seahorse XF instruments are the new standard in cellular bioenergetic measurements. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, Seahorse is headquartered in Billerica, MA. For more information, please visit http://www.seahorsebio.com.

    Seahorse Bioscience, Inc.
    Media Contact: Cynthia Egan
    Phone: 978.671.1610


'/>"/>
SOURCE Seahorse Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
2. Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
3. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
4. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... the publishing of the latest paper by its Science Editor, Dr. Elisabeth Bik, ... Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from her ...
(Date:1/18/2017)... 18, 2017 Shareholder rights law firm Johnson ... the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... with the proposed sale of the Company to Eli ... develops small molecules for the acute treatment of migraines. ... had signed a definitive merger agreement with Eli Lilly. ...
(Date:1/18/2017)... 18, 2017  Caris Life Sciences, a leading ... the largest private funder of pancreatic cancer research, ... the impact of immunotherapy in the treatment of ... services to identify potential trial candidates based on ... physicians and study investigators. The Lustgarten Foundation is ...
(Date:1/18/2017)... India , Jan. 18, 2017  Market Research Future published ... Diagnostics Market is expected to grow at a CAGR of 12% ... ... disease caused due to the abnormal cell division without any control. ... cause harm to them. These cancer cells can spread to other ...
Breaking Biology Technology:
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
(Date:12/15/2016)... Dec 15, 2016 ... Research and Markets has announced the addition of ... The report forecasts the global military biometrics market to ... The report has been prepared based on an in-depth market analysis ... its growth prospects over the coming years. The report also includes a ...
(Date:12/15/2016)... -- "Increase in mobile transactions is driving the growth ... is expected to grow from USD 4.03 billion in ... CAGR of 29.3% between 2016 and 2022. The market ... for smart devices, government initiatives, and increasing penetration of ... expected to grow at a high rate during the ...
Breaking Biology News(10 mins):